BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-exelixis-zanzalintinib-stellar-mid2026-readout@catalyst-calendar.local
DTSTAMP:20260720T200621Z
DTSTART:20260715T130000Z
DTEND:20260715T133000Z
SUMMARY:Exelixis STELLAR-304非透明细胞肾癌三期顶线数据读出窗口
DESCRIPTION:Exelixis此前披露STELLAR-304顶线结果预计在2026年中期读出。该三期研究评估zanzalintinib联合nivolumab对比sunitinib一线治疗晚期非透明细胞肾癌，主要终点包括PFS和ORR。\\nImpact score: 70\\nExpected: 顶线PFS/ORR是否达到统计学和临床意义；关注与sunitinib相比的疗效、安全性和后续申报路径。\\nAffected: EXEL(subject\, unknown\, score 86)\; BMY(peer\, mixed\, score 56)\; MRK(peer\, mixed\, score 54)\; XBI(etf\, mixed\, score 46)\\nSources: Exelixis FY2025 preliminary results: https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-preliminary-fiscal-year-2025-financial\\nClinicalTrials.gov NCT05678673: https://clinicaltrials.gov/study/NCT05678673\\nExelixis STELLAR-304 initiation release: https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-initiation-stellar-304-phase-3-pivotal-trial\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-exelixis-zanzalintinib-stellar-mid2026-readout
CATEGORIES:guidance\,US\,clinical readout\,Phase 3\,RCC\,CRC\,TKI\,三期读出\,肾癌\,VEGFR\,nivolumab\,zanzalintinib\,renal cancer
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Exelixis STELLAR-304非透明细胞肾癌三期顶线数据读出窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Exelixis STELLAR-304非透明细胞肾癌三期顶线数据读出窗口
END:VALARM
END:VEVENT
END:VCALENDAR